GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Igi, Inc. (IG) [hlAlert]

Rating:
Neutral IG
up 530.20 %

Igi, Inc. (IG) downgraded to Neutral by ROTH Capital

Posted on: Friday,  Oct 24, 2014  9:25 AM ET by Roth Capital

Roth Capital rated Neutral Igi, Inc. (AMEX: IG) on 10/24/2014. Previously Roth Capital rated Buy Igi, Inc. (AMEX: IG) on 08/07/2013.,
when the stock price was $1.49. Since then, Igi, Inc. has gained 530.20% as of 10/24/2014's recent price of $9.39.
If you would have followed the previous Roth Capital's recommendation on IG, you would have gained 530.2% of your investment in 443 days.

IGI Inc. is a company committed to growth by applying proprietary technologies to achieve cost-effective solutions for varied customer needs. IGI offers the patented Novasome lipid vesicle encapsulation technology which contributes value-added qualities to cosmetics, skin care products, dermatological formulations and other consumer products, providing improved dermal absorption, low potential for irritations, controlled and sustained release as well as improved stability. IGI has licensed Novasome lipid vesicle encapsulation technology to leading global dermatological and skin care companies including Johnson & Johnson Consumer Products, Inc., Estee Lauder Companies, Chattem Inc., Genesis Pharmaceutical, Inc., Apollo Pharmaceutical, Inc. and Vetoquinol USA. IGI sub-licensed the rights to obtain FDA approval for and market IGI's PTH compound using Novasome lipid vesicle encapsulation technology for psoriasis, which is being reformulated for Phase II clinical trials, to Manhattan Pharmaceuticals, Inc.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/24/2014 9:25 AM Hold
None
9.39
as of 10/17/2014
1 Week up  5.21 %
1 Month up  15.34 %
3 Months up  68.31 %
1 YTD up  190.81 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/7/2013 8:25 AM Buy
None
1.49 3.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy